-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
ACR 2022 Weekly Hot Research Forecast, focusing on cutting-edge progress
in the field of lupus.
The 2022 American College of Rheumatology (ACR) Annual Meeting will take place November 10-14 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania – yes, just tomorrow! The most prestigious rheumatology conference in the world is about to open!
At the annual ACR Annual Meeting, influential experts, physicians, health professionals and scientific researchers in the field of rheumatology gather to bring the latest and most cutting-edge rheumatology research and clinical application information
.
Are you excited and looking forward to this annual academic festival? Are you wondering what this year's ACR Annual Meeting will bring us?
Intimate as a small editor, I have sorted out the essence
of the content in the field of lupus in the conference for you in advance.
Dear rheumatism colleagues, come and check!
Wandering and Cries: Unmet Clinical Needs
in the Field of Lupus Abstract Number: 0353Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes? Study: Steroid diabetes in LN patients: is it a classic risk factor or a different type of diabetes?
Abstract number: 2072 Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index Study: Estimating the incidence of LN corticosteroid-related diseases: Glucocorticoid toxicity index (GTI).
Abstract number: 0345 Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations:A Multiple Logistic Regression Analysis Study: Association between accumulation of hydroxychloroquine and development of cardiac conduction changes in SLE patients: multivariate logistic regression analysis
abstract number: 1186 The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States Study: Disease processes of multiple comorbidities in patients with systemic lupus erythematosus (SLE) in the United States
Abstract number: 2197 Unmet Need in Systemic Lupus Erythematosus(SLE)Therapy:High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US STUDY: Unmet need for SLE treatment: high corticosteroid use and poor treatment adherence and persistence in patients (US)
Abstract number: 2076 Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus Study: In the current clinical management of patients with SLE, traditional immunosuppressants are associated with adverse outcomes in patients
1347Poor Health-Related Quality of Life in Patients with Lupus Nephritis study: The importance of poor quality of life
and prevention of relapse in patients with lupus nephritis (LN): The sooner, the better; The longer, the better
2077Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis? Research: Does early complete remission prevent adverse outcomes with LN?
2061Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis: The impact of time to remission, relapse, and duration of immunosuppressant use on the development of advanced chronic kidney disease in patients with LN
Abstract number: 1450 Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis.
The effect
of the time of onset and the duration of use of immunosuppressants after complete remission on glomerular filtration rate in patients with LN Summary number: 2065 Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares: Sustained B-cell depletion in LN patients after treatment with B-cell pathway is associated with reduced disease episodes
0347Real-World Effectiveness of Belimumab in Patients with SLE in the United States study: The effectiveness
of belimumab in the real world treatment of SLE patients in the United States
TheEffect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus:A Single-center Retrospective Study Study: Belimumab for SLE Achieves Low Disease Activity or Remission (Based on SLEDAS Scores): A Single-Center Retrospective Study
Beware of "Wolf"
0319Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy Study: Factors
associated with worsening interstitial fibrosis/tubular atrophy in LN patients undergoing repeat kidney biopsies
The Effect of Belimumab (BEL) on Kidney Outcomes in SLE:Results of a Large Integrated Analysis Study: Effect of belimumab treatment on renal prognosis in patients with SLE: summary number
of results of a large meta-analysis: 0979 Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus:A Pooled Post Hoc Analysis of Five Phase 3,Randomized,Placebo-Controlled Clinical Trials Study: Effects of belimumab treatment on skin lesions in SLE patients: a pooled analysis
of five phase 3 randomized placebo-controlled clinical trials 0348 Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use–a Systematic Review and Meta-Analysis Study: Berimumab treatment resulted in a significant improvement in cutaneous lupus erythematosus (CLE) with or without SLE: a systematic review and meta-analysis
2088 Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort study: Achieving SLE disease control or low disease activity is associated with lower rates of organ damage progression: results
from the Hopkins Lupus cohort
1463Short-and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria Research: Short- and long-term progression of renal involvement in SLE patients with mild proteinuria Conventional treatment, while important, has limitations!
0349Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus study: risk of
infection with belimumab versus oral immunosuppressants in patients with non-renal involvement SLE
0367Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use Study: Comparison of the use of different immunosuppressants Risk of COVID-19
infection in SLE patients Summary number: 0961 The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series Study: Use of belimumab before and during pregnancy in patients with SLE: an Italian multicenter case series
Clinical and pathological work closely together, what exactly do these evaluation indicators reflect?
0634Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis Study: Global interstitial inflammation in LN patients predicts the progression of
chronic kidney disease Abstract number: 0655 Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents: The inflammatory characteristics of fibrous crescents were identified by proteomic analysis of LN histological lesions
2097Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohortof Patients with Lupus Nephritis Study: Renal biopsy NIH activity score versus chronic score and clinical outcome in the LN patient cohort
Abstract number: 1636 Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort Study: Effects of renal remission on long-term renal survival in LN patients in the Toronto Lupus Cohort
Abstract number: 0362 The Renal Activity Index for Lupus(RAIL)Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis Research: The Lupus Renal Activity Index (RAIL) can be used to identify active kidney disease in SLE patients, how does the longitudinal score correlate
with the renal remission of LN and how can the ideal of individualized treatment be realized, and can biomarkers provide new ideas?
0977Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE) Study: Effect of belimumab treatment on B cell and serum biomarker in SLE patients: Pooled analysis results of a large efficacy study (Be-SLE).
0640Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features Study: Heterogeneity of LN renal immune cells and their relationship
with histopathological features Summary number: 1655 Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus Study: Belimumab interferes with the migration
of memory B cells in SLE patients
Abstract number: 2096 Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus Study: The role of cell-bound complement fragments in assessing disease activity in SLE patients
Abstract number: 0333 Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis: Autoantibody trajectories correlate
with LN classification and treatment response
Abstract number: 0536 Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria Study: Urine is raw at 3 months compared to proteinuriaChanges in biomarkers were better
at predicting response to LN treatment at 1 yearAbstract number: 0537 Neutrophil extracellular traps as a biomarker to predict outcomes in Lupus Nephritis: Neutrophil extracellular traps (NETs) can be used as biomarkers
for predicting LN prognosis
0636Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment study: serum soluble mediators can reflect the histological characteristics and treatment response
of LN The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis: Urine C9/CD59 ratio in relation to LN tubulointerstitial fibrosis
Abstract number: 1135 Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy Study: Complement C3 and complement factor I (CFI) in urine are potential markers
of LN with interstitial fibrosis and tubular atrophy Abstract number: 1478 Urine ALCAM Is a Strong Predictor of Lupus Nephritis: Urine ALCAM is a powerful predictor
of LN
0648Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients Study: In some patients with LN, pathogenic anti-C1q antibodies enhance the activation
of the classical complement pathway Summary number: 0327 SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus Study: SMART-SLE: Serological monitoring and repeat detection of anti-ds-DNA antibodies in SLE patients
Abstract number: 0978 Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic,Non-pathogenic Phenotype in Systemic Lupus Erythematosus STUDY: Treatment of SLE with belimumab after rituximab targets the production of IgA2 anti-ds-DNA antibodies and enables the transition of recombinant B cells to a non-pathogenic, non-allergenic phenotype
total
knot
We will continue to pay attention to the exciting hot content in lupus-related areas at the 2022 ACR Annual Meeting and follow up on them
.
The conference content is colorful and exciting, in the torrent of information, we will provide you with timely and effective cutting-edge information, and select hot content for in-depth interpretation, stay tuned!
This article is only for providing scientific information to healthcare professionals and does not represent the position of
the platform.
